TELA Bio, Inc. (TELA) stock
TELANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.78+0.02 (+2.36%)
Close on Nov 18, 2026Market cap $35.02MP/E –Yield –
TELA Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
TELA Bio's operating income for the twelve months ending Jun 30, 2026 was -$34.01M. For fiscal 2025 it was -$33.76M. The highest annual figure on record is -$16.92M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$33.76M | – |
| FY2024 | Dec 31, 2024 | -$34.12M | – |
| FY2023 | Dec 31, 2023 | -$44.08M | – |
| FY2022 | Dec 31, 2022 | -$39.01M | – |
| FY2021 | Dec 31, 2021 | -$29.45M | – |
| FY2020 | Dec 31, 2020 | -$25.28M | – |
| FY2019 | Dec 31, 2019 | -$19.16M | – |
| FY2018 | Dec 31, 2018 | -$17.78M | – |
| FY2017 | Dec 31, 2017 | -$16.92M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.28M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.53M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.65M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.55M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.08M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.47M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.35M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.37M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.57M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.28M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.18M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.36M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.25M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.44M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.49M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.24M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.84M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.22M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.31M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.27M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.75M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.86M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.17M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.50M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.30M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.18M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.50M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.52M | – |
See a number that looks wrong?